NCT04156633

Brief Summary

In this before-after study, different new methods for bacterial species identification from positive blood cultures will be compared towards historic controls. All samples are analyzed within the routine workflow for bacterial species identification and antibiotic resistance profiling. Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls) will be compared to patients from 2018 and 2019 with a new identification method (cases). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or Matrix-assisted Laser-Desorption/Ionization Time-of-Flight (MALDI-TOF MS). The new identification of positive blood cultures methods include (i) either the newly introduced Biofire FilmArray© Blood Culture Identification (BCID) panel or (ii) in a subset of patients whole genome sequencing (WGS) approaches.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 17, 2019

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

November 5, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 7, 2019

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2022

Completed
Last Updated

May 9, 2024

Status Verified

May 1, 2024

Enrollment Period

2.4 years

First QC Date

November 5, 2019

Last Update Submit

May 7, 2024

Conditions

Keywords

MALDI-TOF MSBiofire FilmArray© Blood Culture Identification (BCID) panelshotgun metagenomic approach

Outcome Measures

Primary Outcomes (1)

  • Time to optimal antibiotic treatment in hours from positive blood cultures (hours)

    Time from blood draw for blood culture testing to start of optimal antibiotic treatment (hours)

    24 hours from collection of blood cultures

Secondary Outcomes (4)

  • Time to effective antibiotic treatment in hours from positive blood cultures (hours)

    24 hours from collection of blood cultures

  • all-cause in hospital mortality (number)

    from admission to hospital until release from hospital (approximately 30 days)

  • duration on ICU in days

    from admission to ICU until release from ICU (approximately 20 days)

  • time to Gram staining and resistance profile from positive blood cultures (hours)

    24 hours from collection of blood cultures

Study Arms (3)

conventional identification methods (controls)

Patients with positive blood cultures from 2016 to 2018 receiving a conventional identification methods (controls). The conventional identification method consisted in general of an over-night subculture and subsequent identification of the bacterial pathogen using either biochemical profiling or MALDI-TOF MS.

Diagnostic Test: conventional identification method: biochemical profiling or MALDI-TOF MS

new identification method (cases)Biofire FilmArray© BCID panel

Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).

Diagnostic Test: new identification method: Biofire FilmArray© BCID panel

new identification method (cases) WGS approaches

Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification of positive blood cultures methods in a subset of patients is a whole genome sequencing approach. This so called shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene.

Diagnostic Test: new identification method: metagenomic WGS

Interventions

Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)

conventional identification methods (controls)

The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)

new identification method (cases)Biofire FilmArray© BCID panel

shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)

new identification method (cases) WGS approaches

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with positive blood cultures hospitalized at the university hospital Basel between August 2016 and October 2019 are included.

You may qualify if:

  • patients with positive blood cultures hospitalized between August 2016 and October 2019
  • documented refusal of the general consent

You may not qualify if:

  • outpatients
  • patients hospitalized in other hospitals
  • patients with known bacteremia diagnosed in another hospital

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division of Clinical Bacteriology & Mycology, University Hospital Basel

Basel, 4031, Switzerland

Location

Related Publications (1)

  • Agnetti J, Buchler AC, Osthoff M, Helfenstein F, Weisser M, Siegemund M, Bassetti S, Bingisser R, Schaefer DJ, Clauss M, Hinic V, Tschudin-Sutter S, Battig V, Khanna N, Egli A. Identification of microorganisms by a rapid PCR panel from positive blood cultures leads to faster optimal antimicrobial therapy - a before-after study. BMC Infect Dis. 2023 Oct 26;23(1):730. doi: 10.1186/s12879-023-08732-9.

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Adrian Egli, PD Dr. med

    Division of Clinical Bacteriology & Mycology; University Hospital Basel

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 5, 2019

First Posted

November 7, 2019

Study Start

October 17, 2019

Primary Completion

March 1, 2022

Study Completion

July 31, 2022

Last Updated

May 9, 2024

Record last verified: 2024-05

Locations